Eyepoint Pharmaceuticals Inc (EYPT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.88 (-2.76%), Market cap $1.05B, 52-week low–high $5.60 ~ $18.85.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2
Financial statements, price targets, institutional (13F) holdings and related news for Eyepoint Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Eyepoint Pharmaceuticals Inc trades at $3.88 (-2.76%). Real-time quotes and charts are available on BlackAll Trade.
Eyepoint Pharmaceuticals Inc has a market cap of about $1.05B.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Duras